332 filings
8-K
INMB
INmune Bio Inc
30 May 24
Other Events
4:00pm
DEF 14A
INMB
INmune Bio Inc
Definitive proxy
29 May 24
4:05pm
8-K
INMB
INmune Bio Inc
23 May 24
Amendments to Articles of Incorporation or Bylaws
4:00pm
8-K
INMB
INmune Bio Inc
16 May 24
Departure of Directors or Certain Officers
4:00pm
8-K
INMB
INmune Bio Inc
10 May 24
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a
7:46pm
8-K
8y09or65n ka
30 Apr 24
Other Events
4:01pm
8-K
ms4ffshjvd0ow9
26 Apr 24
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:28pm
424B5
7pk0k zpa3
26 Apr 24
Prospectus supplement for primary offering
4:26pm
8-K
7cvu0kpv 80gvxvf
25 Apr 24
Other Events
4:35pm
8-K
8uhfpv
22 Apr 24
Entry into a Material Definitive Agreement
5:10pm
424B5
s9404uz51fg1a
22 Apr 24
Prospectus supplement for primary offering
5:09pm
8-K
zbjvy5sxsoz
9 Apr 24
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
4:58pm
8-K
wvit13
29 Mar 24
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
4:01pm
8-K
a72ipgx krki
27 Mar 24
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
4:07pm
8-K
yqqu31x5g5qi
30 Jan 24
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
8:02am
8-K
3lqqteydde1i9lxctm
2 Jan 24
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
4:00pm